Zenas BioPharma, Inc. financial data

Symbol
ZBIO on Nasdaq
Location
852 Winter Street, Suite 250, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 661 %
Debt-to-equity 17.1 %
Return On Equity -59.2 % -362%
Return On Assets -50.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.1M shares
Common Stock, Shares, Outstanding 42.1M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 4K USD
Weighted Average Number of Shares Outstanding, Basic 41.9M shares +2571%
Weighted Average Number of Shares Outstanding, Diluted 41.9M shares +2571%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Revenue from Contract with Customer, Excluding Assessed Tax 10M USD
Research and Development Expense 161M USD +27.3%
General and Administrative Expense 43.5M USD +106%
Operating Income (Loss) -189M USD -38.9%
Nonoperating Income (Expense) 12.3M USD +71.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -52.2M USD -37.5%
Income Tax Expense (Benefit) 20K USD
Net Income (Loss) Attributable to Parent -177M USD -223%
Earnings Per Share, Basic 28 USD/shares +94.8%
Earnings Per Share, Diluted 28 USD/shares +94.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44M USD -76.1%
Cash, Cash Equivalents, and Short-term Investments 275M USD
Assets, Current 279M USD
Property, Plant and Equipment, Net 61K USD
Operating Lease, Right-of-Use Asset 1.01M USD
Other Assets, Noncurrent 11.8M USD
Assets 293M USD
Accounts Payable, Current 7.93M USD
Employee-related Liabilities, Current 6.05M USD
Accrued Liabilities, Current 44.5M USD
Liabilities, Current 53.2M USD
Operating Lease, Liability, Noncurrent 215K USD
Liabilities 53.5M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -94K USD
Retained Earnings (Accumulated Deficit) -473M USD
Stockholders' Equity Attributable to Parent 240M USD
Liabilities and Equity 293M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.1M USD -94%
Net Cash Provided by (Used in) Financing Activities 99K USD
Net Cash Provided by (Used in) Investing Activities -86.3M USD -392055%
Common Stock, Shares Authorized 175M shares -40.6%
Common Stock, Shares, Issued 42.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -123M USD -526%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44M USD -76.1%
Deferred Tax Assets, Valuation Allowance 90.3M USD +127%
Deferred Tax Assets, Gross 90.9M USD +127%
Operating Lease, Liability 1.01M USD
Depreciation 23K USD -30.3%
Payments to Acquire Property, Plant, and Equipment 18K USD -18.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -177M USD -38.2%
Lessee, Operating Lease, Liability, to be Paid 1.06M USD
Operating Lease, Liability, Current 793K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 137K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 455K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -38.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 51K USD
Deferred Tax Assets, Operating Loss Carryforwards 29.6M USD +197%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 713M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 19.8M USD +294%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares